Immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors, can block the interaction between PD-1 and PD-L1, restore T cell activity, and enable them to recognize and attack tumor cells (85). This evidence concerns the gene CD274 and neoplasm.